American Association for Cancer Research
Browse
10780432ccr140586-sup-128171_1_supp_2599193_n9wd9x.docx (28.19 kB)

Supplemental Table 2 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia

Download (28.19 kB)
journal contribution
posted on 2023-03-31, 18:47 authored by Michael Boyiadzis, Mukta Arora, John P. Klein, Anna Hassebroek, Michael Hemmer, Alvaro Urbano-Ispizua, Joseph H. Antin, Brian J. Bolwell, Jean-Yves Y. Cahn, Mitchell S. Cairo, Corey S. Cutler, Mary E. Flowers, Robert P. Gale, Roger Herzig, Luis M. Isola, David A. Jacobsohn, Madan H. Jagasia, Thomas R. Klumpp, Stephanie J. Lee, Effie W. Petersdorf, Stella Santarone, Stephen R. Spellman, Harry C. Schouten, Leo F. Verdonck, John R. Wingard, Daniel J. Weisdorf, Mary M. Horowitz, Steven Z. Pavletic

Supplemental Table 2. Multivariate analysis showing impact of cGVHD characteristics in CML patients on relapse

History

ARTICLE ABSTRACT

Purpose: Malignancy relapse remains a major obstacle for successful allogeneic hematopoietic cell transplantation (HCT). Chronic graft-versus-host disease (cGVHD) is associated with fewer relapses. However, when studying effects of cGVHD on relapse, it is difficult to separate from acute GVHD effects as most cases of cGVHD occur within the first year after transplant at the time when acute GVHD is still active.Experimental Design: This study based on CIBMTR registry data investigated cGVHD and its association with the incidence of late relapse and survival in 7,489 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and myelodysplastic syndromes (MDS), who were leukemia free at 12 months after myeloablative allogeneic HCT.Results: Forty-seven percent of the study population was diagnosed with cGVHD at 12 months after transplant. The protective effect of cGVHD on late relapse was present only in patients with CML [RR, 0.47; 95% confidence interval (CI), 0.37–0.59; P < 0.0001). cGVHD was significantly associated with higher risk of treatment-related mortality (TRM; RR, 2.43; 95% CI, 2.09–2.82; P < 0.0001) and inferior overall survival (RR, 1.56; 95% CI, 1.41–1.73; P < 0.0001) for all diseases. In patients with CML, all organ sites and presentation types of cGVHD were equally associated with lower risk of late relapse.Conclusions: These results indicate that clinically relevant antileukemia effects of cGVHD on late relapses are present only in CML but not in AML, ALL, or MDS. Chronic GVHD in patients who are 1-year survivors after myeloablative allogeneic HCT is primarily associated with higher TRM and inferior survival. Clin Cancer Res; 21(9); 2020–8. ©2014 AACR.See related commentary by Gill, p. 1981

Usage metrics

    Clinical Cancer Research

    Categories

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC